期刊文献+

美罗华联合CTOP方案治疗B细胞非霍奇金淋巴瘤35例临床分析 被引量:8

Clinical Analysis of the Effect of Rituximab in Combination with CTOP Chemotherapy on B Cell Non-Hodgkin's Malignant Lymphoma
下载PDF
导出
摘要 目的:评价美罗华联合环磷酰胺、吡柔比星、长春新碱、泼尼松(R-CTOP方案)治疗B细胞非霍奇金淋巴瘤的疗效及不良反应,分析影响疗效的相关因素。方法:回顾性分析我院35例经病理证实为CD20+的B细胞非霍奇金淋巴瘤患者的临床资料,评估R-CTOP方案化疗的疗效及不良反应,分析性别、年龄、疾病分期、病理类型、LDH水平及IPI评分等影响疗效的相关因素。结果:35例患者中33例可评价疗效,其中完全缓解(CR)17例(51.5%),部分缓解(PR)11例(33_3%),有效率(CR+PR)84.8%。23例初治患者中,CR13例(56.5%),PR8例(34.8%),有效率(CR+PR)91_3%;10例复发难治患者中,CR4例(40%),PR3例(30%),有效率70%。疗效与性别、疾病分期、病理类型、LDH水平及IPI评分等因素无显著相关,年龄对疗效有一定影响(P=0.012)。35例患者中无治疗相关死亡,不良反应主要为骨髓抑制(Ⅲ~Ⅳ度白细胞下降32.1%),心脏毒性和脱发较轻,主要为Ⅰ~Ⅱ级反应。其它不良反应经对症处理后均可耐受。结论:R-CTOP方案治疗B细胞非霍奇金淋巴瘤有效率高且不良反应轻微,可作为治疗B细胞非霍奇金淋巴瘤特别是老年非霍奇金淋巴瘤患者的优先选择。 Objective: To evaluate the efficacy and toxicity of rituximab combined with cyclophosphamide, pirarubicin, vincristine, and prednisone (R-CTOP regimen) for B cell non-Hodgkin's lymphoma and to analyze the influential factors for patient response.Methods: The clinical data of patients with CD20 antigen treated with R-CTOP regimen were reviewed and the influence of sex, age, clinical stage, pathological type, and level of LDH and IPI on patient response was analyzed.Results: A total of 33 patients were evaluated for objective response.The complete response (CR) rate was 51.5%, the par-ticel response (PR) rate was 33.3%, and the overall response rate was 84.8%.For the 23 de novo patients, the CR rate was 56.5 %, the PR rate was 34.8%, and the OR rate was 91.3%.While in the 10 recurrent patients, the CR rate was 40%, the PR rate was 30%, and the OR rate was 70%.Sex, clinical stage, pathological type, and the level of LDH and IPI were not significantly related to clinical response.While patient age was related to clinical response.None of the patients died of therapy-related side effects.The most frequent adverse event was myelosuppression (Ⅲ-Ⅳ decrease of leukocyte account-ed for 32.1%).Cardiotoxicity and alopecia were mostly grade Ⅰ to grade Ⅱ.Other side effects can be tolerated after symp-tomatic treatment.Conclusion: R-CTOP regimen is a highly effective and well-toleraed therapy and should be the first choice in the treatment for B cell non-Hodgkin's lymphoma (NHL), especially for senior patients.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2010年第6期338-341,共4页 Chinese Journal of Clinical Oncology
关键词 利妥昔单抗 非霍奇金淋巴瘤 化疗 Rituximab Non-Hodgkin's lymphoma Chemotherapy
  • 相关文献

参考文献5

  • 1Swain SM,Whaley FS,Ewer MS.Gongestive heart failure in patients treated with doxorubicin:a retrospective analysis of three trials[J].Gancer,2003,97:2869-2879.
  • 2Feuqier P,van Hoof A,Sebban G,etal.Long-term results of the R-CHOP study of elderly patients with diffuse large B-cell lymphoma:A study by the Group Etude des lymphoma de LAdute.J Glin Oncol,2005,18(23):4117-4126.
  • 3VOSE JM,LINK BK,GROSS BARD ML et al.Prase Ilsmdy of rituximab in combination with CHOP chemotherapy in patients with previously untreated,aggressive non-Hodgkin's lymphoma.J Clin Oncol,2001,19(2):389-397.
  • 4夏忠军,王风华,黄慧强,骆卉妍,李宇红,林桐榆,姜文奇,管忠震.含美罗华方案治疗B细胞性惰性淋巴瘤34例报告[J].癌症,2006,25(4):490-494. 被引量:9
  • 5杜芹,杨锡贵.利妥昔单抗联合化疗治疗复发B细胞恶性淋巴瘤的回顾性分析[J].中国肿瘤临床,2009,36(4):203-206. 被引量:5

二级参考文献28

  • 1黄慧强,卜庆,夏忠军,林旭滨,王风华,李宇红,彭玉龙,潘战和,王树森,林桐榆,姜文奇,管忠震.含美罗华联合方案治疗复发耐药B细胞性非霍奇金淋巴瘤[J].癌症,2006,25(4):486-489. 被引量:9
  • 2Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas[J]. Blood, 2003,101 (3) : 949-954.
  • 3Forero A, Lobuglio AF.History of antibody therapy for non-Hodgkin's lymphoma[]]. Semin Oncol, 2003, 30(6 Suppl 17): 1-5.
  • 4VoseJM, Link BK, Grossbard ML, et al. Phase Ⅱ study of rituximab in combination with chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma[J]. J Clin Oncol, 2001, 19(2): 389-397.
  • 5Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of padents with relapsing or refractory aggressive lyrnphoma: a multicenter phase Ⅱ study [J]. Blood, 1998, 92(6): 1927-1932.
  • 6Jermann M,Jost LM, Taverna Ch, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase Ⅱ study[J]. Ann Oncol, 2004, 15(3): 511-516.
  • 7Tsutsumi Y, Kawamura T, Saitoh S, et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy[J]. Leuk Lymphoma, 2004, 45(3): 627-629.
  • 8Sera T, Hiasa Y, Michitaka K, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab[J]. Intern Med, 2006, 45(11): 721-724.
  • 9Garcia-Rodriguez MJ, Canales MA, Hemandez-Maraver D, et al. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment [J]? Am J Hematol, 2008, 83(3): 673-675.
  • 10Zinzani P L,Pulsoni A,Perrotti A,et al.Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma[J].J Clin Oncol,2004,22 (13):2654-2661.

共引文献11

同被引文献56

引证文献8

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部